Kisspeptin and Oxytocin Interaction: Synergistic | Peptide Database

Multiple randomized controlled trials have demonstrated that berberine (500 mg 2-3x daily) reduces fasting blood glucose by 15-25% and HbA1c by 0.5-0.9% in individuals with type 2 diabetes or insulin resistance. A landmark 2008 study in Metabolism showed berberine was comparable to metformin in glycemic control over a 3-month period. Particularly useful for individuals seeking a non-prescription approach to glucose management. Berberine consistently reduces total cholesterol by 15-20%, LDL cholesterol by 20-25%, and triglycerides by 25-35% across clinical trials. Its PCSK9-inhibitory activity provides a unique lipid-lowering mechanism distinct from statins. May be used alone or as adjunctive therapy alongside other lipid-lowering interventions. Improves insulin sensitivity through multiple mechanisms including AMPK activation and insulin receptor upregulation. Reduces HOMA-IR scores in clinical studies. A practical option for individuals with prediabetes or metabolic syndrome who prefer a supplement-based approach before initiating pharmaceutical therapy. Widely used in the biohacking community to counteract the blood glucose elevations associated with MK-677 (ibutamoren) and exogenous growth hormone use. MK-677 can raise fasting glucose by 5-15 mg/dL through GH-mediated insulin resistance, and berberine's AMPK activation helps offset this effect. Often dosed at 500 mg with the evening meal when MK-677 is taken at night. AMPK activity declines with age, contributing to metabolic dysfunction, reduced autophagy, and increased inflammation. Berberine's potent AMPK activation may help counteract age-related metabolic decline. Preclinical studies suggest berberine extends lifespan in several model organisms, though human longevity data is limited to indirect metabolic biomarker improvements. The combination of glucose-lowering, lipid-lowering, and anti-inflammatory effects positions berberine as a compound with potential cardiovascular benefits. Clinical trials have shown improvements in endothelial function and reductions in carotid intima-media thickness. However, long-term cardiovascular outcome trials have not been conducted. Berberine has demonstrated significant effects on gut microbiota composition, increasing populations of Akkermansia muciniphila and other beneficial bacteria associated with improved metabolic health. These microbiome changes may account for a meaningful portion of berberine's systemic metabolic effects, as much of the compound remains in the gut due to its low oral bioavailability.

VIP inhalation shows striking efficacy with increased mixed venous oxygen saturation and exercise capacity. Dilates peripheral blood vessels through NO-dependent mechanisms above 100 pmol doses. Coronary vasodilation with positive inotropic and chronotropic effects on the heart. Promising therapeutic target for Alzheimer's, Parkinson's, and other neurological disorders. Potential therapeutic target being researched for ASD. Produced in suprachiasmatic nuclei; involved in circadian regulation. Promotes insulin secretion in glucose-dependent manner via VPAC2; low hypoglycemia risk. Potent anti-inflammatory effects useful in IBD and autoimmune conditions. Therapeutic potential for pulmonary and systemic sarcoidosis.